InvestSMART

Mayne Pharma Group Limited (ASX: MYX) - Announcements

Current share price for MYX : $2.540 0.02 (0.79%)+

ASX company news and announcements for Mayne Pharma Group Limited (MYX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mayne Pharma Group Limited (MYX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mayne Pharma Group Limited (MYX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mayne Pharma Group Limited (MYX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$208 Change of Director's Interest Notice 13 Sep 2016 4:15PM $1.938 $2.540 risen by 31.10%
$208 Change in substantial holding from WBC 1 Sep 2016 4:34PM $1.915 $2.540 risen by 32.64%
$208 2016 Full Year Results Investor Presentation 26 Aug 2016 8:23AM $1.920 $2.540 risen by 32.29%
$208 2016 Full Year Results Media Release 26 Aug 2016 8:22AM $1.920 $2.540 risen by 32.29%
$208 Appendix 4E, Directors Report and Financial Statements 26 Aug 2016 8:21AM $1.920 $2.540 risen by 32.29%
$208 Appendix 3B 25 Aug 2016 3:27PM $1.920 $2.540 risen by 32.29%
$208 Appendix 3B 22 Aug 2016 4:46PM $2.000 $2.540 risen by 27%
$208 Response to ASX Appendix 3Y Query 19 Aug 2016 9:12AM $2.050 $2.540 risen by 23.90%
$208 Investor Presentation Acquisition of GSK Foam Assets 18 Aug 2016 9:30AM $2.020 $2.540 risen by 25.74%
$208 MYX announces acquisition of US foam dermatology assets 18 Aug 2016 9:25AM $2.020 $2.540 risen by 25.74%
$208 Change of Director's Interest Notice 16 Aug 2016 1:12PM $2.070 $2.540 risen by 22.71%
$208 Appendix 3B 11 Aug 2016 5:07PM $2.030 $2.540 risen by 25.12%
$208 Appendix 3B 4 Aug 2016 10:37AM $2.000 $2.540 risen by 27%
$208 Completion of US generic product acquisition from Teva 3 Aug 2016 3:24PM $2.010 $2.540 risen by 26.37%
$208 MYX announces settlement from patent infringement case 29 Jul 2016 10:16AM $1.973 $2.540 risen by 28.77%
$208 Change in substantial holding from WBC 27 Jul 2016 4:37PM $1.940 $2.540 risen by 30.93%
$208 Change of Director's Interest Notice 27 Jul 2016 11:41AM $1.945 $2.540 risen by 30.59%
$208 Ceasing to be a substantial holder from BTT 26 Jul 2016 4:32PM $1.950 $2.540 risen by 30.26%
$208 Appendix 3B 22 Jul 2016 10:55AM $1.938 $2.540 risen by 31.10%
$208 Change in substantial holding from BTT 21 Jul 2016 4:51PM $1.965 $2.540 risen by 29.26%
$208 Retail Entitlement Offer completion and scale back policy 20 Jul 2016 9:19AM $1.985 $2.540 risen by 27.96%
$208 Change to option exercise price and Appendix 3B 15 Jul 2016 10:48AM $1.970 $2.540 risen by 28.93%
$208 Change of Director's Interest Notice 13 Jul 2016 2:17PM $1.980 $2.540 risen by 28.28%
$208 Change of Director's Interest Notices (x5) 7 Jul 2016 3:03PM $1.810 $2.540 risen by 40.33%
$208 Section 708A notice 7 Jul 2016 8:55AM $1.800 $2.540 risen by 41.11%

776 - 800 of 904 results

Page 32 of 37

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.